In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925001540 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765812333707264 |
|---|---|
| author | Michal Geva Ralf Reilmann Robin Schubert Kelly Chen Y Paul Goldberg Michael R. Hayden |
| author_facet | Michal Geva Ralf Reilmann Robin Schubert Kelly Chen Y Paul Goldberg Michael R. Hayden |
| author_sort | Michal Geva |
| collection | DOAJ |
| format | Article |
| id | doaj-art-71aed8b677ab43b1a0e48db3c0153f77 |
| institution | DOAJ |
| issn | 1878-7479 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurotherapeutics |
| spelling | doaj-art-71aed8b677ab43b1a0e48db3c0153f772025-08-20T03:04:45ZengElsevierNeurotherapeutics1878-74792025-07-01224e0067610.1016/j.neurot.2025.e00676In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington diseaseMichal Geva0Ralf Reilmann1Robin Schubert2Kelly Chen3Y Paul Goldberg4Michael R. Hayden5Prilenia Therapeutics B.V.George Huntington InstituteGeorge Huntington InstitutePrilenia Therapeutics B.V.Prilenia Therapeutics B.V.Prilenia Therapeutics B.V.http://www.sciencedirect.com/science/article/pii/S1878747925001540 |
| spellingShingle | Michal Geva Ralf Reilmann Robin Schubert Kelly Chen Y Paul Goldberg Michael R. Hayden In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease Neurotherapeutics |
| title | In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease |
| title_full | In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease |
| title_fullStr | In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease |
| title_full_unstemmed | In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease |
| title_short | In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease |
| title_sort | in the phase 3 proof hd trial pridopidine shows consistent motor function improvements in q motor measures supporting q motor as a predictive measure of long term functional benefit and slower progression cuhdrs in huntington disease |
| url | http://www.sciencedirect.com/science/article/pii/S1878747925001540 |
| work_keys_str_mv | AT michalgeva inthephase3proofhdtrialpridopidineshowsconsistentmotorfunctionimprovementsinqmotormeasuressupportingqmotorasapredictivemeasureoflongtermfunctionalbenefitandslowerprogressioncuhdrsinhuntingtondisease AT ralfreilmann inthephase3proofhdtrialpridopidineshowsconsistentmotorfunctionimprovementsinqmotormeasuressupportingqmotorasapredictivemeasureoflongtermfunctionalbenefitandslowerprogressioncuhdrsinhuntingtondisease AT robinschubert inthephase3proofhdtrialpridopidineshowsconsistentmotorfunctionimprovementsinqmotormeasuressupportingqmotorasapredictivemeasureoflongtermfunctionalbenefitandslowerprogressioncuhdrsinhuntingtondisease AT kellychen inthephase3proofhdtrialpridopidineshowsconsistentmotorfunctionimprovementsinqmotormeasuressupportingqmotorasapredictivemeasureoflongtermfunctionalbenefitandslowerprogressioncuhdrsinhuntingtondisease AT ypaulgoldberg inthephase3proofhdtrialpridopidineshowsconsistentmotorfunctionimprovementsinqmotormeasuressupportingqmotorasapredictivemeasureoflongtermfunctionalbenefitandslowerprogressioncuhdrsinhuntingtondisease AT michaelrhayden inthephase3proofhdtrialpridopidineshowsconsistentmotorfunctionimprovementsinqmotormeasuressupportingqmotorasapredictivemeasureoflongtermfunctionalbenefitandslowerprogressioncuhdrsinhuntingtondisease |